About PDL Biopharma (NASDAQ:PDLI)
PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:PDLI
CUSIP69329Y10
Phone775-832-8500
Debt
Debt-to-Equity Ratio0.14%
Current Ratio3.32%
Quick Ratio3.27%
Price-To-Earnings
Trailing P/E Ratio4.60
Forward P/E Ratio9.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$320.06 million
Price / Sales1.39
Cash Flow$0.8788 per share
Price / Cash3.30
Book Value$5.48 per share
Price / Book0.53
Profitability
EPS (Most Recent Fiscal Year)$0.63
Net Income$110.74 million
Net Margins34.60%
Return on Equity12.03%
Return on Assets7.81%
Miscellaneous
Employees87
Outstanding Shares153,810,000
PDL Biopharma (NASDAQ:PDLI) Frequently Asked Questions
What is PDL Biopharma's stock symbol?
PDL Biopharma trades on the NASDAQ under the ticker symbol "PDLI."
How will PDL Biopharma's stock buyback program work?
PDL Biopharma announced that its board has authorized a stock buyback program on Monday, September 25th 2017, which authorizes the company to repurchase $25,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board believes its shares are undervalued.
How were PDL Biopharma's earnings last quarter?
PDL Biopharma (NASDAQ:PDLI) released its quarterly earnings data on Thursday, March, 8th. The biotechnology company reported $0.17 EPS for the quarter. The biotechnology company earned $68.04 million during the quarter. PDL Biopharma had a net margin of 34.60% and a return on equity of 12.03%. View PDL Biopharma's Earnings History.
When is PDL Biopharma's next earnings date?
What price target have analysts set for PDLI?
2 brokerages have issued 1 year target prices for PDL Biopharma's shares. Their predictions range from $3.00 to $4.00. On average, they anticipate PDL Biopharma's share price to reach $3.50 in the next twelve months. View Analyst Ratings for PDL Biopharma.
What are Wall Street analysts saying about PDL Biopharma stock?
Here are some recent quotes from research analysts about PDL Biopharma stock:
- 1. According to Zacks Investment Research, "PDL BioPharma’s earnings surpassed estimates in fourth-quarter 2017. The company is focused on acquiring and managing income-generating assets. It has royalty agreements with several companies, whereby it receives royalties on sales of their products. We are positive on the company’s recent strategic shift, wherein, it is making equity investments in product-focused companies. The company’s investment on Noden Pharma, focused on acquiring and optimizing established medicines, is also encouraging. Its shares have outperformed the industry in the past one year. However, the company is heavily dependent on its partners for royalty revenues, which is not a risk-free strategy. We are also concerned about PDL BioPharma’s revenue stream as its growth prospects rely on the timing and ability to acquire new income-generating assets for recurring revenues." (3/14/2018)
- 2. Cowen Inc analysts commented, "PDL reported an in-line Q1 with both total revenue ($45MM vs $43MM) and EPS." (5/3/2017)
Who are some of PDL Biopharma's key competitors?
Some companies that are related to PDL Biopharma include La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS), Novavax (NVAX), Jounce Therapeutics (JNCE), Heska (HSKA), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), EntreMed (CASI), Mesoblast (MESO), BioCryst Pharmaceuticals (BCRX), Solid Biosciences (SLDB), Vericel (VCEL), Nightstar Therapeutics (NITE), Agenus (AGEN), Cellular Biomedicine (CBMG), Idera Pharmaceuticals (IDRA), Adverum Biotechnologies (ADVM) and NantKwest (NK).
Who are PDL Biopharma's key executives?
PDL Biopharma's management team includes the folowing people:
- Mr. John Peter McLaughlin J.D., CEO & Director (Age 66)
- Mr. Peter S. Garcia, VP & CFO (Age 56)
- Mr. Steffen Pietzke, VP of Fin. & Chief Accounting Officer (Age 46)
- Mr. Christopher L. Stone J.D., VP, Gen. Counsel & Sec. (Age 54)
- Mr. Dominique P. Monnet, Pres (Age 57)
Has PDL Biopharma been receiving favorable news coverage?
Media coverage about PDLI stock has trended somewhat negative recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. PDL Biopharma earned a news impact score of -0.02 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.38 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of PDL Biopharma?
Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PDL Biopharma's stock price today?
One share of PDLI stock can currently be purchased for approximately $2.90.
How big of a company is PDL Biopharma?
PDL Biopharma has a market capitalization of $446.05 million and generates $320.06 million in revenue each year. The biotechnology company earns $110.74 million in net income (profit) each year or $0.63 on an earnings per share basis. PDL Biopharma employs 87 workers across the globe.
How can I contact PDL Biopharma?
PDL Biopharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]
MarketBeat Community Rating for PDL Biopharma (PDLI)
MarketBeat's community ratings are surveys of what our community members think about PDL Biopharma and other stocks. Vote "Outperform" if you believe PDLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
PDL Biopharma (NASDAQ:PDLI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for PDL Biopharma in the last 12 months. Their average twelve-month price target is $3.50, suggesting that the stock has a possible upside of 20.69%. The high price target for PDLI is $4.00 and the low price target for PDLI is $3.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.50 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $3.50 | $3.50 | $3.50 | $4.00 |
| Price Target Upside: | 20.69% upside | 18.24% upside | 18.24% upside | 51.52% upside |
PDL Biopharma (NASDAQ:PDLI) Consensus Price Target History
PDL Biopharma (NASDAQ:PDLI) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/27/2017 | Cowen | Reiterated Rating | Hold | $3.00 | N/A |  |
| 8/10/2017 | Piper Jaffray | Reiterated Rating | Buy | $4.00 | Medium | |
(Data available from 4/22/2016 forward)
PDL Biopharma (NASDAQ:PDLI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/4/2016 | quarterly | $0.05 | 6.25% | 6/2/2016 | 6/6/2016 | 6/13/2016 |
| 2/1/2016 | quarterly | $0.05 | 7.27% | 3/2/2016 | 3/4/2016 | 3/11/2016 |
| 2/2/2015 | quarterly | $0.15 | 8.22% | 6/1/2016 | 6/5/2016 | 6/12/2016 |
| 1/30/2015 | quarterly | $0.15 | 8.23% | 6/3/2015 | 6/5/2015 | 6/12/2015 |
| 1/30/2015 | quarterly | $0.15 | 8.23% | 3/3/2015 | 3/5/2015 | 3/12/2015 |
| 1/30/2015 | quarterly | $0.15 | 8.23% | 12/2/2015 | 12/4/2015 | 12/11/2015 |
| 1/30/2015 | quarterly | $0.15 | 8.23% | 9/2/2015 | 9/4/2015 | 9/11/2015 |
| 1/31/2014 | quarterly | $0.15 | 6.59% | 9/3/2014 | 9/5/2014 | 9/12/2014 |
| 1/31/2014 | quarterly | $0.15 | 6.59% | 3/3/2014 | 3/5/2014 | 3/12/2014 |
| 1/31/2014 | quarterly | $0.15 | 6.59% | 12/3/2014 | 12/5/2014 | 12/12/2014 |
| 1/31/2014 | quarterly | $0.15 | 6.59% | 6/3/2014 | 6/5/2014 | 6/12/2014 |
| 1/31/2013 | quarterly | $0.15 | 8.72% | 12/3/2013 | 12/5/2013 | 12/12/2013 |
| 1/31/2013 | quarterly | $0.15 | 8.72% | 6/3/2013 | 6/5/2013 | 6/12/2013 |
| 1/31/2013 | quarterly | $0.15 | 8.72% | 9/3/2013 | 9/5/2013 | 9/12/2013 |
| 1/30/2013 | quarterly | $0.15 | 8.72% | 3/1/2013 | 3/5/2013 | 3/12/2013 |
(Data available from 1/1/2013 forward)
PDL Biopharma (NASDAQ PDLI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 91.40%
PDL Biopharma (NASDAQ PDLI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/24/2017 | Peter S Garcia | VP | Buy | 25,000 | $1.98 | $49,500.00 | 452,492 | |
| 8/9/2016 | Peter S Garcia | VP | Buy | 10,000 | $3.00 | $30,000.00 | 232,092 | |
| 12/15/2015 | Peter S. Garcia | CFO | Buy | 5,000 | $3.64 | $18,200.00 | 126,041 | |
| 12/14/2015 | Peter S. Garcia | CFO | Buy | 10,000 | $3.42 | $34,200.00 | 126,041 | |
| 12/7/2015 | Steffen Pietzke | CAO | Buy | 20,590 | $3.64 | $74,947.60 | | |
| 8/14/2015 | Peter S Garcia | CFO | Buy | 20,000 | $5.83 | $116,600.00 | | |
| 11/26/2014 | Harold E Selick | Director | Buy | 6,000 | $8.08 | $48,480.00 | | |
(Data available from 1/1/2013 forward)
PDL Biopharma (NASDAQ PDLI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | PDL Biopharma (PDLI) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - April 19 at 12:49 PM |
 | Form 8-K PDL BIOPHARMA, INC. For: Apr 16
www.streetinsider.com - April 17 at 5:28 PM |
 | Technical Perspectives on Biotech Stocks -- Pain Therapeutics, Paratek Pharma, PDL BioPharma, and Progenics Pharma
www.bizjournals.com - April 16 at 8:44 AM |
 | PDL BioPharma to Hold Annual Meeting of Stockholders on June 8, 2018
finance.yahoo.com - April 16 at 8:44 AM |
| BidaskClub Downgrades PDL Biopharma (PDLI) to Sell
www.americanbankingnews.com - April 14 at 10:43 AM |
| Head-To-Head Survey: Curis (CRIS) versus PDL Biopharma (PDLI)
www.americanbankingnews.com - April 14 at 1:11 AM |
| PDL Biopharma (PDLI) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 12 at 11:47 AM |
| PDL Biopharma's (PDLI) "Buy" Rating Reiterated at Piper Jaffray
www.americanbankingnews.com - April 10 at 10:30 PM |
 | PDL BioPharma (PDLI) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 5:05 PM |
| PDL BioPharma Shareholder, SevenSaoi Capital, Comments on the Nomination of Shlomo Yanai to the PDL Board of Directors and Delivers Letter to the Board Outlining Significant Concerns
finance.yahoo.com - April 10 at 9:05 AM |
| PDL Biopharma (PDLI) Rating Lowered to Hold at ValuEngine
www.americanbankingnews.com - April 9 at 11:35 AM |
| ValuEngine Upgrades PDL Biopharma (PDLI) to Buy
www.americanbankingnews.com - April 8 at 11:17 AM |
| Analysts Anticipate PDL Biopharma (PDLI) Will Announce Earnings of $0.06 Per Share
www.americanbankingnews.com - April 7 at 3:22 AM |
| PDL Biopharma (PDLI) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - April 6 at 10:46 AM |
| PDL Biopharma's (PDLI) "Hold" Rating Reiterated at Cowen
www.americanbankingnews.com - April 4 at 5:52 PM |
| PDL BioPharma to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - April 3 at 5:05 PM |
| Is PDL BioPharma, Inc. a Buy?
finance.yahoo.com - March 27 at 9:05 AM |
| Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal
finance.yahoo.com - March 20 at 4:52 PM |
| PDL Biopharma (PDLI) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 18 at 11:40 AM |
| Is PDL BioPharma (PDLI) a Great Stock for Value Investors Right Now?
finance.yahoo.com - March 16 at 6:02 PM |
| PDL BioPharma (PDLI) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 14 at 6:31 PM |
| PDL BioPharma (PDLI) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 14 at 12:44 PM |
| PDL BioPharma (PDLI) Lifted to C- at TheStreet
www.americanbankingnews.com - March 13 at 12:19 PM |
 | PDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/Y - Nasdaq
www.nasdaq.com - March 11 at 8:47 AM |
| PDL BioPharma (PDLI) Upgraded at BidaskClub
www.americanbankingnews.com - March 10 at 5:31 PM |
 | PDL BioPharma Vaults on Q4 Figures
www.baystreet.ca - March 9 at 6:13 PM |
| PDL BioPharma posts 4Q profit
finance.yahoo.com - March 8 at 6:06 PM |
| PDL BioPharma Announces Fourth Quarter and Year End 2017 Financial Results
finance.yahoo.com - March 8 at 6:06 PM |
| Will PDL BioPharma Inc (NASDAQ:PDLI) Continue To Underperform Its Industry?
finance.yahoo.com - March 8 at 8:57 AM |
 | Quotidian Technical Highlights on Selected Biotech Stocks -- Paratek Pharma, PDL BioPharma, Progenics Pharma, and Prothena
www.prnewswire.com - March 7 at 8:53 AM |
| Mackenzie Financial Corp Reduces Stake in PDL BioPharma Inc (PDLI)
www.americanbankingnews.com - March 6 at 12:08 PM |
| PDL BioPharma Inc (PDLI) Expected to Post Earnings of $0.03 Per Share
www.americanbankingnews.com - March 4 at 1:08 AM |
| PDL BioPharma to Announce Fourth Quarter / Year-End 2017 Financial Results on March 8, 2018
finance.yahoo.com - March 1 at 8:39 AM |
| PDL BioPharma (PDLI) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - February 28 at 8:20 PM |
| Kestrel Investment Management Corp Sells 45,700 Shares of PDL BioPharma Inc (PDLI)
www.americanbankingnews.com - February 28 at 4:14 PM |
| PDL BioPharma Inc (PDLI) Stake Lessened by Fuller & Thaler Asset Management Inc.
www.americanbankingnews.com - February 28 at 12:10 PM |
| Richard L. Lindstrom, M.D. Joins LENSAR, Inc. Board of Directors
finance.yahoo.com - February 26 at 5:24 PM |
| Systematic Financial Management LP Has $1.65 Million Position in PDL BioPharma Inc (PDLI)
www.americanbankingnews.com - February 26 at 3:56 PM |
| PDL BioPharma Inc (PDLI) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 21 at 11:42 AM |
| Is PDL BioPharma Inc (NASDAQ:PDLI) A Buy At Its Current PE Ratio?
finance.yahoo.com - February 21 at 8:50 AM |
| PDL BioPharma (PDLI) Terminates Interest in Pursuing Acquisition of Neos (NEOS)
www.streetinsider.com - February 20 at 8:39 AM |
| PDL BioPharma Terminates Interest in Pursuing Acquisition of Neos
finance.yahoo.com - February 20 at 8:39 AM |
| PDL BioPharma (PDLI) Downgraded by BidaskClub to Strong Sell
www.americanbankingnews.com - February 19 at 4:02 PM |
| Brokerages Expect PDL BioPharma Inc (PDLI) Will Post Earnings of $0.03 Per Share
www.americanbankingnews.com - February 15 at 8:58 AM |
| PDLI Feb 2018 2.000 call
finance.yahoo.com - February 15 at 8:13 AM |
| PDL BioPharma (PDLI) to Release Earnings on Wednesday
www.americanbankingnews.com - February 14 at 2:56 AM |
| What Are the Best Healthcare Stocks to Buy? Here Are a Top AI System's 5 Favorites
finance.yahoo.com - February 8 at 8:30 AM |
| PDL BioPharma Inc (PDLI) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 27 at 11:56 AM |
| PDL BioPharma (PDLI) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 8 at 12:38 PM |
| PDL BioPharma (PDLI) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - January 6 at 5:06 PM |
PDL Biopharma (NASDAQ:PDLI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
PDL Biopharma (NASDAQ:PDLI) Income Statement, Balance Sheet and Cash Flow Statement
PDL Biopharma (NASDAQ PDLI) Stock Chart for Sunday, April, 22, 2018
Loading chart…
